C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 213/02 (2006.01) A61K 31/38 (2006.01) A61K 31/44 (2006.01) C07D 403/02 (2006.01) C07D 417/02 (2006.01)
Patent
CA 2532064
The present invention is directed to compounds of Formula I: I (where variables R1, R2, R3 and R4 are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to the use of such compounds as ligands of AM receptors for the treatment or prevention of diseases in which AM is involved, such as cancer. The invention is further directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP and/or AM are involved.
L'invention concerne des composé représentés par la formule I (dans laquelle les variables R?1¿, R?2¿, R?3¿ et R?4¿ sont définies ci-après) utilisés comme antagonistes des récepteurs peptide dérivé gène calcitonine (CGRP) et pour traiter et prévenir des maladies impliquant CGRP, telles que les céphalées, les migraines et les céphalées vasculaires de Horton. L'invention concerne également l'utilisation de ces composés comme ligands des récepteurs AM afin de traiter et prévenir des maladies impliquant AM, telles que le cancer. L'invention concerne enfin des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et de compositions pour traiter et prévenir des maladies impliquant CGRP et/ou AM.
Bell Ian M.
Gallicchio Steven N.
Zartman C. Blair
Merck & Co. Inc.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Hydroxypyridine cgrp receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxypyridine cgrp receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxypyridine cgrp receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1895618